Evidence map›Paper›PMID 34902205›Full record

ArticleCancer science2022

RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.

Tatsuya Masuda, Shintaro Maeda, Sae Shimada, Naoya Sakuramoto, Ken Morita, Asami Koyama, Kensho Suzuki, Yoshihide Mitsuda, Hidemasa Matsuo, Hirohito Kubota and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. RUNX1 promotes liver fibrosis progression through regulating TGF-β signalling.International journal of experimental pathology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

Tatsuya MasudaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shintaro MaedaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-8932-2051
Sae ShimadaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Naoya SakuramotoDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ken MoritaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Asami KoyamaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kensho SuzukiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshihide MitsudaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hidemasa MatsuoDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hirohito KubotaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Itaru KatoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-2932-4960
Kuniaki TanakaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masahiro HirataDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.ORCID https://orcid.org/0000-0001-9211-0511
Tatsuki R KataokaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Tatsutoshi NakahataDepartment of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Souichi AdachiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hideyo HiraiDepartment of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan.
Shuichi MizutaHematology & Immunology, Kanazawa Medical University, Uchinada, Kahoku-gun, Japan.
Kazuhito NakaResearch Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoichi ImaiDepartment of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2938-6133
Shinya KimuraFaculty of Medicine, Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga University, Saga, Japan.ORCID https://orcid.org/0000-0003-1717-6208
Hiroshi SugiyamaDepartment of Chemistry, Graduate School of Science, Kyoto University, Kyoto, Japan.
Yasuhiko KamikuboDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0003-2761-8508
Kyoto University · JPKyoto University Hospital · JPHiroshima University · JPKanazawa Medical University · JPSaga University · JPTokyo Medical University Hospital · JP

Funding

Japan Agency for Medical Research and Development 15am0301005h0002Japan Agency for Medical Research and Development 19am0101101j0003Japan Society for the Promotion of Science 17H03597
6 · The paper itself

Abstract

The emergence of tyrosine kinase inhibitors as part of a front-line treatment has greatly improved the clinical outcome of the patients with Ph

Indexed as

AnimalsAntineoplastic AgentsCell DeathCell Line, TumorCell ProliferationCore Binding Factor Alpha 2 SubunitDrug Resistance, NeoplasmFusion Proteins, bcr-ablGene Expression Regulation, NeoplasticHumansImatinib MesylateMiceMutationPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsAntineoplastic AgentsBCR-ABL1 fusion protein, humanCore Binding Factor Alpha 2 SubunitFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsRUNX1 protein, humanbcr-ablfusion proteinsgene expression regulationleukemialymphoidPhiladelphia chromosomeRUNX1 protein, human

Identifiers

PMID34902205
PMCPMC8819354
OpenAlexW4200564706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.